Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study

Atopic Dermatitis

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ

doi: 10.1111/jdv.20724

Atopic Dermatitis

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Kridin S, Mayer E, Sawaed W, Ludwig RJ

doi: 10.1111/jdv.20864

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Atopic Dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

J Am Acad Dermatol

Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z, Marco AR

doi: 10.1016/j.jaad.2024.09.039

Atopic Dermatitis

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

JAMA Dermatol

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY

doi: 10.1001/jamadermatol.2025.1578

Atopic Dermatitis

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

JAMA Ophthalmol

Chu YY, Sung CH, Lin YS, Ho CH, Chen YC, Lee WA, Kuo SC

doi: 10.1001/jamaophthalmol.2025.0366

Atopic Dermatitis

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

J Allergy Clin Immunol Pract

Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T, FRench Atopic DErmatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group

doi: 10.1016/j.jaip.2024.12.001

Atopic Dermatitis

Risk Factors for Moderate-Severe Asthma In Children Ages 5-11 Years with Early-onset Atopic Dermatitis

J Allergy Clin Immunol Pract

Zeiger RS, Schatz M, Zhou B, Stern JA, Li Q, Stanford RH, Shams M, Avella H, Subramaniam A, Chen W

doi: 10.1016/j.jaip.2025.07.036

Osteoporosis

Long Dosing Intervals of Parenteral Antiosteoporosis Medications and the Decrease in Societal Fracture Risk: A 11-Year Nationwide Population-Based Cohort Study

Mayo Clin Proc

Fu SH, Yen HK, Yang RS, Hung CC, Lin JW, Lee MT, Chen HM, Wu CH, Hsu CC, Li CY, Groot OQ, Wang CY

doi: 10.1016/j.mayocp.2024.05.002

Related content

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

Risk Factors for Moderate-Severe Asthma In Children Ages 5-11 Years with Early-onset Atopic Dermatitis

Long Dosing Intervals of Parenteral Antiosteoporosis Medications and the Decrease in Societal Fracture Risk: A 11-Year Nationwide Population-Based Cohort Study